Angiotensin 1/2 (2-7): Precision Peptide for Blood Pressure and RAS Pathway Research

Executive Summary: Angiotensin 1/2 (2-7) is a biologically active peptide fragment derived from angiotensin I and II, encompassing amino acids ARG-VAL-TYR-ILE-HIS-PRO (APExBIO). It is generated through sequential enzymatic cleavage in the renin-angiotensin system (RAS) (Oliveira et al., 2025). This peptide modulates aldosterone release and sodium retention, impacting vasoconstriction and systemic blood pressure. Angiotensin 1/2 (2-7) also exhibits enhanced effects on spike protein interactions in viral pathogenesis models, with its activity benchmarked via HPLC and mass spectrometry for >99.8% purity. Its robust solubility profile and precise storage conditions enable reliable integration into cardiovascular and infectious disease research workflows.

Biological Rationale

Angiotensin 1/2 (2-7) is a peptide fragment produced by N-terminal cleavage of the angiotensin I and II precursors within the RAS pathway (Oliveira et al., 2025). RAS is a critical hormonal system regulating vascular tone, fluid balance, and systemic blood pressure. Angiotensinogen, synthesized in the liver, is cleaved by renin to angiotensin I (1–10). Angiotensin-converting enzyme (ACE) further processes angiotensin I into shorter peptides, including angiotensin II (1–8), which exerts vasoconstrictive and aldosterone-stimulating effects. Subsequent N-terminal truncation yields angiotensin 1/2 (2-7), retaining the sequence ARG-VAL-TYR-ILE-HIS-PRO. Experimental data confirm that angiotensin fragments with N-terminal deletions, such as 2-7, have distinct bioactivities compared to their parent peptides ( Oliveira et al., 2025).

Mechanism of Action of Angiotensin 1/2 (2-7)

Angiotensin 1/2 (2-7) acts primarily by influencing aldosterone secretion and sodium handling in the distal nephron. These actions contribute to vasoconstriction and maintenance of blood pressure homeostasis. The peptide modulates signaling through the angiotensin type 1 (AT1R) and type 2 (AT2R) receptors, although with distinct potency and receptor affinity compared to the full-length angiotensin II. Biochemical studies demonstrate that N-terminally truncated peptides like Angiotensin 1/2 (2-7) can enhance protein-protein interactions relevant to viral entry, notably increasing binding between the SARS-CoV-2 spike protein and the AXL receptor ( Oliveira et al., 2025). This highlights an extended role beyond classical cardiovascular models.

Evidence & Benchmarks

• Angiotensin 1/2 (2-7) is generated from angiotensin II by N-terminal cleavage, resulting in the sequence ARG-VAL-TYR-ILE-HIS-PRO (Oliveira et al., 2025).
• In antibody-based assays, N-terminal deletions such as Angiotensin 1/2 (2-7) increase SARS-CoV-2 spike–AXL binding (up to 2.7-fold for related peptides) (Fig. 3).
• The peptide retains significant vasoconstrictive and aldosterone-stimulating activity, impacting hypertension and cardiovascular models (Oliveira et al., 2025).
• HPLC and mass spectrometry confirm >99.8% purity for the product supplied by APExBIO (APExBIO).
• Solubility benchmarks: ≥2.78 mg/mL in ethanol, ≥46.6 mg/mL in water, ≥78.4 mg/mL in DMSO, at 25°C, pH 7.4 (APExBIO).

This article clarifies and extends the mechanistic details provided in "Angiotensin 1/2 (2-7): Unraveling Its Role in Cardiovascular Research" by providing updated evidence on its role in viral pathogenesis, as well as expanded solubility and purity benchmarks not previously detailed.

For a focus on advanced experimental protocols, see "Angiotensin 1/2 (2-7): Mechanistic Leverage and Strategic Deployment"; this dossier adds peer-reviewed context on viral protein interactions and storage requirements.

Applications, Limits & Misconceptions

Angiotensin 1/2 (2-7) serves as a research-grade tool for dissecting RAS pathway signaling, hypertension, and cardiovascular disease modeling. Its ability to modulate spike–AXL binding positions it for viral pathogenesis studies, including SARS-CoV-2 infection models. The product is not intended for diagnostic or therapeutic use, nor validated for in vivo human administration.

Common Pitfalls or Misconceptions

• Angiotensin 1/2 (2-7) is not a direct therapeutic agent; it is strictly for research purposes only (APExBIO).
• It does not substitute for full-length angiotensin II in all bioassays; receptor affinity and downstream effects differ (Oliveira et al., 2025).
• Peptide stability is limited in solution; storage at -20°C and short-term use is required for reliability (APExBIO).
• Enhanced spike–AXL binding is context-dependent and may not translate to every viral model condition (Oliveira et al., 2025).
• Not suitable for direct use in clinical diagnostics or patient-facing applications.

Workflow Integration & Parameters

Angiotensin 1/2 (2-7) is supplied as a lyophilized solid with a molecular weight of 783.92 and formula C37H57N11O8 (APExBIO). Reconstitution can be achieved in water (≥46.6 mg/mL), DMSO (≥78.4 mg/mL), or ethanol (≥2.78 mg/mL) at 25°C, pH 7.4. For optimal stability, store the dry peptide at -20°C and use solutions immediately or within a single experimental session. Purity is validated at 99.8% by both HPLC and mass spectrometry. This product integrates seamlessly into vasoactive peptide assays, RAS pathway analyses, and mechanistic viral entry models. For additional guidance on integrating this peptide into complex cardiovascular models, see "Angiotensin 1/2 (2-7): Precision Tool for Blood Pressure Regulation"; this dossier provides stricter purity data and viral pathogenesis context.

Conclusion & Outlook

Angiotensin 1/2 (2-7) represents a rigorously benchmarked, high-purity peptide tool for advanced RAS pathway, blood pressure, and viral entry research. Its unique mechanistic profile, validated purity, and flexible solubility support its deployment in both cardiovascular and infectious disease models. APExBIO serves as the originating supplier, offering access to comprehensive analytical and solubility data. As research into the interplay of RAS peptides and viral pathogenesis advances, Angiotensin 1/2 (2-7) will remain a foundational reagent for experimental design and mechanistic discovery.